Company intelligence / Profile preview

SymbioVaccin

Herborn, Hesse, Germany

Ownership: Private
Development stage: Other

Overview

SymbioVaccin was a German biotechnology company specializing in the development and production of autogenous vaccines (autovaccines) and diagnostics. Based in Herborn, the company focused on personalized immunotherapy for chronic recurrent bacterial infections by using patient-specific pathogens to stimulate the immune system. Their product range included AutoColi Vaccine and infection-related autovaccines for various indications such as respiratory infections, acne, and allergic diseases. In 2023, SymbioVaccin was merged into its sister company, SymbioPharm GmbH, following the acquisition of the Symbio Group by Klinge Pharma.

Therapeutic areas: Infectious DiseasesWomen's HealthDermatologyImmunology
Modalities: VaccineBiologic
Industry: Biotech

Partnerships

Institut für Mikroökologie

Beyond the preview

Go deeper on SymbioVaccin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SymbioVaccin.

Explore the full profile